Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Genzyme receives positive CHMP opinion in the European Union for once-daily, oral AUBAGIO® to treat relapsing-remitting multiple sclerosis
Glatiramer acetate, an anti-demyelination drug, reduced rats' epileptic seizures induced by pentylenetetrazol via protection of myelin sheath.
Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
Gut Microbiota in Multiple Sclerosis: Possible Influence of Immunomodulators.
Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
Zebrafish myelination: a transparent model for remyelination?
A genetic screen identifies genes essential for development of myelinated axons in zebrafish.
FDA approval letter for daclizumab for the prophylaxis of acute organ rejection in patients receiving renal transplants
Effect of IFN β-1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients.
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
BTG plc Close Period Update
[Neuromyelitis optica following thymectomy with severe spinal cord atrophy after frequent relapses for 30 years].
Effect of Glatiramer Acetate on Peripheral Blood Brain-Derived Neurotrophic Factor and Phosphorylated TrkB Levels in Relapsing-Remitting Multiple Sclerosis.
Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research.
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple scl
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.
Limit cycle oscillations in standing human posture.
A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis.
Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease.
The scales and tales of myelination: using zebrafish and mouse to study myelinating glia.

Pages